Tuberculosis (TB) is the most frequent cause of death from a single infectious agent. Active disease follows about 5% of exposures, but most develop a 'latent' infection without symptoms that may reactivate later, particularly during immune deficiency. Live M. bovis bacillus Calmette-Guerin (BCG) is the only currently available vaccine but has had negligible impact on the global epidemic. Indeed, the rise of HIV infection has raised serious safety concerns, with disseminated infection reported in HIV-seropositives following BCG vaccination. Clearly there is an urgent need for safer, more effective vaccination for protective responses that, ideally, will prevent or contain latent TB infection. We have recently shown that consecutive immunization with DNA vaccines and attenuated fowlpoxvirus vectors encoding similar vaccine antigens generates high levels of antigen-specific, interferon-gamma-secreting CD4+ and CD8+ T cells that, importantly, exhibit markedly increased sensitivity (avidity) for the immunizing antigen. In terms of memory, antigen challenge led to rapid expansion of systemic and mucosal T cell effectors in vaccinated animals, reaching levels as high as 30% of total T cell numbers. Mucosal T cells may be particularly important in pulmonary TB, where little attention has been paid to local immune responses. Here, our primary aim is to test the hypothesis that T cell responses induced by prime-boost vaccination will control primary TB infection and the establishment or reactivation of latent infection. Our goal is to generate protective T cell responses against key antigens of M. tuberculosis (MTb) normally expressed (i) in acute infection and (ii) during progression to a nonreplicating persistent state. The latter are poorly studied but are of central importance to our proposal, since they represent novel and highly selective targets for vaccine strategies that may forestall or contain latent infection. Specifically, we will test the protective efficacy of systemic prime-boosting against (i) low-dose aerosol challenge with MTb and (ii) reactivation in murine models of latent TB disease. We will also study (iii) the protective capacity of prime-boost vaccines given mucosally and characterize systemic and mucosal (pulmonary) CD4+ and CD8+ T cell responses in these models. Co-delivery of IL-15 genes will be tested for their ability to enhance magnitude and memory of T cell immunity. The capacity of our approach to generate strong, sustained Th1-type CD4+ and CD8+ T cell responses is highly attractive in the context of TB and HIV infection, where maintenance of such responses against key proteins of MTb may be critical for protection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI058810-05
Application #
7388167
Study Section
Special Emphasis Panel (ZRG1-VACC (01))
Program Officer
Lacourciere, Karen A
Project Start
2004-04-01
Project End
2010-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
5
Fiscal Year
2008
Total Cost
$198,126
Indirect Cost
Name
Louisiana State Univ Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Rady, Hamada F; Dai, Guixiang; Huang, Weitao et al. (2016) Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant. PLoS One 11:e0148701
Dai, Guixiang; Rady, Hamada F; Huang, Weitao et al. (2016) Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B. Vaccine 34:6267-6275
Dalmia, Neha; Klimstra, William B; Mason, Carol et al. (2015) DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection. PLoS One 10:e0136635
Dalmia, Neha; Ramsay, Alistair J (2012) Prime-boost approaches to tuberculosis vaccine development. Expert Rev Vaccines 11:1221-33
Auten, Matthew W; Huang, Weitao; Dai, Guixiang et al. (2012) CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals. Vaccine 30:2768-77
Porretta, Elizabeth; Happel, Kyle I; Teng, Xu S et al. (2012) The impact of alcohol on BCG-induced immunity against Mycobacterium tuberculosis. Alcohol Clin Exp Res 36:310-7
Ranasinghe, Charani; Eyers, Fiona; Stambas, John et al. (2011) A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. Vaccine 29:3008-20
Happel, Kyle I; Lockhart, Euan A; Mason, Carol M et al. (2005) Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs. Infect Immun 73:5782-8